📄 Direct examination of Dr. John Gerdes (part 5) — Wednesday, August 2, 1995
Address:
C:\DEPT103\CRIMINAL\1995\AUG\2\DIRECT-EXAMINATION-OF-DR-JOHN-.DOC
TRIAL
▲ Day 127 of 167

Direct examination of Dr. John Gerdes (part 5)

Witness: Dr. John Gerdes
Examiner: Barry Scheck
Called by: Defense • Date: Wednesday, August 2, 1995 • Utterances: 188
Barry Scheck continued his direct examination of DNA expert Dr. John Gerdes, focusing on LAPD criminalist Yamauchi's handling of OJ Simpson's reference blood sample alongside evidence samples on the morning of June 14th. Gerdes testified that processing a high-DNA reference sample (which spilled and aerosolized) in the same time and location as low-DNA evidence swatches violated standard forensic protocols and created unacceptable contamination risk. The defense used this testimony to suggest that DNA results from the Rockingham glove — particularly sections G10, G11, and G13 — could be the product of cross-contamination rather than genuine Simpson blood.
1 MR. SCHECK:

Now, when DNA samples such as the swatches, the kind of red swatches you are dealing with in this case, when they are degraded, what does that do in terms of the risk of cross-contamination once they are in a DNA laboratory?

2 MR. CLARKE:

Objection, no foundation.

3 THE COURT:

Sustained.

4 MR. SCHECK:

All right. Do you have familiarity with the processes that were used for handling the swatches in this case?

5 DR. GERDES:

Yes.

6 MR. SCHECK:

Are you familiar with the testimony of Mr. Fung and Miss Mazzola about how they took the red swatches out of plastic bags and placed them in test-tubes on the evening of June 13th?

7 DR. GERDES:

Yes.

8 MR. SCHECK:

All right. Have you seen their testimony about that?

9 DR. GERDES:

I have.

10 MR. SCHECK:

Have you seen the evidence packaging boards that describe that?

11 DR. GERDES:

Yes.

12 MR. SCHECK:

All right. Have you--are you familiar with their testimony with respect to the next day taking the blood swatches out of the tubes and scraping them with a pipette, putting them in the white papers that they call bindles, folding them up?

13 DR. GERDES:

I am familiar with that.

14 MR. SCHECK:

Are you familiar with how they then put those bindles into coin envelopes?

15 DR. GERDES:

Yes.

16 MR. SCHECK:

Are you familiar with the testimony of Mr. Yamauchi as to what he did on the morning of June 14th, starting at around 9:00 A.M. through 11:20 A.M. when he processed the reference sample of Mr. Simpson, the Rockingham glove and the Bundy swatches, 47, 48, 49, 50 and 52?

17 DR. GERDES:

I am familiar with that.

18 MR. SCHECK:

Have you reviewed that testimony?

19 DR. GERDES:

Yes.

20 MR. SCHECK:

Now, if one were to assume that the Bundy samples, that is, the swatches 47, 48, 49, 50 and 52 were degraded, would that increase the risk of cross-contamination?

21 MR. CLARKE:

Objection, assumes facts not in evidence, also lack of foundation.

22 THE COURT:

Sustained.

23 MR. SCHECK:

Well, assumes facts not in evidence. In your opinion, sir, in terms of the handling of samples in a DNA laboratory, are there problems when one is handling degraded samples with low amounts or no DNA at the same time or period or location when handling samples with high contents of DNA.

24 MR. CLARKE:

Objection, no foundation.

25 THE COURT:

Overruled.

26 DR. GERDES:

Yes, there definitely are problems under those circumstances.

27 MR. SCHECK:

And is that a situation which increases the risk of cross-contamination?

28 DR. GERDES:

Yes.

29 MR. SCHECK:

And why is that?

30 DR. GERDES:

Well, I also believe at the very beginning of my testimony I described the fact that if you have something in high concentration next to something in low concentration there is a greater chance that you can get small amounts of material from the substance with high concentration into the one with low, and so there is a greater risk of that kind of cross-contamination because you are handling the two at the same time next to each other.

31 THE COURT:

And the nodding of the jurors indicate that they recollect that from this trial, too, and they recollect it from a month ago.

KEY QUOTE
32 MR. SCHECK:

Well, it was a month ago. All right.

33 MR. SCHECK:

Now, are there rules or practices, to your knowledge, in the various protocols for handling samples in forensic labs in other DNA laboratories with respect to handling a reference sample in the same location and in the same period as evidence samples?

34 MR. CLARKE:

Objection, no foundation.

35 THE COURT:

Overruled.

36 DR. GERDES:

Yes, there are definite protocols for that.

37 MR. SCHECK:

And what are those protocols and what is your understanding of those practices? What are the rules?

38 DR. GERDES:

The rules are that you never handle a reference sample at the same time as any evidence.

KEY QUOTE
39 MR. SCHECK:

Now, when you say "At the same time," what are we talking about? Are we talking about--could you please describe that.

40 DR. GERDES:

It means in the--at the same--the same time.

41 MR. CLARKE:

I'm sorry?

42 DR. GERDES:

In terms of--

43 MR. CLARKE:

Objection, calls for speculation.

44 THE COURT:

Overruled.

45 DR. GERDES:

Well, "Same time" means in the same setting I guess is the way I would describe it, and that doesn't mean that it is in a sequence of events. It means that you don't have--you have a separation in time by a matter of a span of at least, you know, twenty minutes or a half an hour. There is no really exact time period, but the way it is described in these protocols, is that you handle the reference sample, you put it away, you bleach down, you totally clean up, you allow a period of time and then you can handle evidence.

46 MR. SCHECK:

In your experience in reviewing the practices at the Cellmark laboratory, how do they handle reference samples and evidence samples?

47 DR. GERDES:

They were handled at the same time.

48 MR. SCHECK:

I'm sorry?

49 DR. GERDES:

At the same time. They were handled at the same time, reference and evidence.

50 MR. SCHECK:

Now, what is their current practice?

51 DR. GERDES:

The LAPD?

52 MR. SCHECK:

No, I'm talking about Cellmark.

53 DR. GERDES:

Oh, Cellmark, excuse me. Cellmark never handles reference samples and evidence at the same time.

54 MR. SCHECK:

How do they do it?

55 DR. GERDES:

I--

56 MR. SCHECK:

Separate it by how much a period?

57 DR. GERDES:

In prior cases when I have inquired of their criminalist, it would be the closest--

58 MR. CLARKE:

I'm sorry, objection. Calls for hearsay.

59 THE COURT:

Sustained.

60 MR. SCHECK:

All right. Are you familiar with--do you know, according to their protocol--withdrawn. Let's get back to LAPD. Are you familiar with the testimony of Mr. Yamauchi that at about nine o'clock--well, let's take care of all foundation items. Are you familiar with the serology item description notes which are 1185, I have shown them to Mr. Clarke, of Mr. Yamauchi for June 14th and June 15th, his notes of handling the samples?

61 DR. GERDES:

Yes.

62 MR. SCHECK:

All right. Are you familiar with his testimony that between the period of 9:00 A.M. and 11:20 A.M. he handled Mr. Simpson's reference sample and created a fitzco card?

63 DR. GERDES:

Yes.

64 MR. SCHECK:

He moved next to the Rockingham glove, did a series of pheno tests and cuttings and initialed that glove?

65 DR. GERDES:

That's correct.

66 MR. SCHECK:

Took samples? And then moved on to do the so-called Bundy blood drop items, 47, 48, 49, 50 and 52? Are you familiar with that?

67 DR. GERDES:

I believe the order was 52 and then the others, but the exact sequence is different than what you stated, but they were done.

68 MR. SCHECK:

They handled the Bundy blood drops all within that period?

69 DR. GERDES:

Yes, they did.

70 MR. SCHECK:

Now, in your judgment was--what is your opinion of this laboratory practice of handling Mr. Simpson's reference tubes in the way Mr. Yamauchi described it and these evidence samples within that period?

71 MR. CLARKE:

Objection, no foundation.

72 THE COURT:

Overruled.

73 DR. GERDES:

That is not an acceptable practice in any forensic laboratory.

KEY QUOTE
74 MR. SCHECK:

Why?

75 DR. GERDES:

Because of the unacceptable risk of contamination from the reference sample which has high levels of DNA and the evidence items that were processed which have low levels.

76 MR. SCHECK:

Now, do you recall that section of Mr. Yamauchi's testimony where he describes that he opened Mr. Simpson's reference sample and blood came out of the tube that went through the chem wipe and onto his glove?

77 DR. GERDES:

Yes, I recall that.

78 MR. SCHECK:

Now, in your experience when you open one of these vacutainer tubes, what happens or what happened?

79 DR. GERDES:

Well, you can hear--

80 MR. CLARKE:

Excuse me. Objection, no foundation.

81 THE COURT:

Overruled.

82 DR. GERDES:

It is a vacutainer. That means it is under vacuum. It is sort of like opening a coffee can, you can hear it and there is an aerosol that is created.

KEY QUOTE
83 MR. SCHECK:

When you say "Aerosol" what do you mean?

84 DR. GERDES:

Aerosol is very small fine mist of droplets that would then spray.

85 MR. SCHECK:

That is of blood?

86 DR. GERDES:

Of blood in this case, yes.

87 MR. SCHECK:

And is in--in terms of the DNA content of a reference tube and that aerosol, how does it compare--what is the nature of the DNA content of--of such a substance?

88 DR. GERDES:

Well, it doesn't take very much blood to have a substantial amount of DNA.

89 MR. SCHECK:

Now, you read Mr. Yamauchi's testimony where you indicated that after he opened the reference tube and the blood went through his chem wipe and went onto his glove that he then disposed of the gloves, he can't recall, either in the evidence processing room or in the serology lab?

90 DR. GERDES:

That is what I remember, yes.

91 MR. SCHECK:

All right. Now, given the nature of his testimony about the way he opened the tube, do you think that what he did next in terms of moving onto the analysis of the other sample was an acceptable laboratory practice?

92 DR. GERDES:

No. I mean, you know, you've had a spillage, you should have basically stopped everything, cleaned down the entire lab and waited for a period of time before you move on to something as critical as evidence items.

93 MR. SCHECK:

All right. Now, the--are you familiar with Dr. Cotton's testimony with respect to the Cellmark and the California association of crime lab directors proficiency study?

94 DR. GERDES:

Yes, I am familiar with that.

95 MR. SCHECK:

And are you familiar with her testimony with respect to how that laboratory got a false positive--false positive errors?

96 DR. GERDES:

Yes.

97 MR. SCHECK:

Do you think that that has any particular application to this situation we are talking about here, the way Mr. Yamauchi handled Mr. Simpson's reference samples and these samples on the morning of June 14th?

98 MR. CLARKE:

Objection, no foundation, calls for speculation.

99 THE COURT:

Sustained.

100 MR. SCHECK:

Are you familiar with the--have you read Dr. Cotton's testimony with respect to the CACLD study?

101 DR. GERDES:

Yes, I have.

102 MR. SCHECK:

Have you looked at literature and letters with respect to the results of that study?

103 DR. GERDES:

Yes, I'm familiar with it.

104 MR. SCHECK:

Is that study discussed in the NRC report?

105 DR. GERDES:

It is discussed in the NRC report.

106 MR. SCHECK:

All right. Now, what is it about Dr. Cotton's testimony and her description of these events that you think has application here.

107 MR. CLARKE:

Same objection.

108 THE COURT:

Sustained.

109 MR. CLARKE:

Also irrelevant.

110 THE COURT:

Sustained.

111 MR. SCHECK:

Can--is it your understanding that Cellmark made a false positive error even though there were witnesses in the room looking at the transfers?

112 MR. CLARKE:

Same objection, same grounds.

113 THE COURT:

Sustained.

114 MR. SCHECK:

Now, could you please describe, just in simple practical terms, why you have stated that Mr. Yamauchi's practices between nine o'clock and 11:20 in handling Mr. Simpson's reference sample, the Rockingham glove and the Bundy blood drops, how in practical terms could that cause cross-contamination?

115 MR. CLARKE:

Objection, lack of foundation.

116 THE COURT:

Overruled.

117 MR. CLARKE:

Also asked and answered.

118 THE COURT:

Overruled.

119 DR. GERDES:

Yes. I mean when you are--you are handling this blood specimen first and it has been admitted that there was a spillage. Now there is blood on the table, there is an aerosol in the air. Now, just as a hypothetical, Mr. Yamauchi has--we have seen his notes. He was obviously writing with a pen. He may have gotten a little blood on that pen, then he walks to the other end of the bench carrying the pen.

120 MR. CLARKE:

I'm sorry, I'm going to object based on speculation, your Honor.

121 THE COURT:

Sustained.

122 MR. CLARKE:

Motion to strike also.

123 THE COURT:

The answer is stricken. The jury is to disregard it.

124 MR. SCHECK:

Let me put it to you this way: In the process of handling DNA samples are mistakes made in terms of cross-contamination that the analyst does realize?

125 MR. CLARKE:

Objection, lack of foundation.

126 THE COURT:

Overruled.

127 DR. GERDES:

Yes.

128 MR. SCHECK:

I call your attention to page 89 of the NRC report and I would like to have this marked as--what is the next in order?

129 THE COURT:

1299, I believe--I'm sorry, what page, counsel?

130 MR. SCHECK:

Page 89 and I am at 1299.

131 THE COURT:

1299.

132 MR. SCHECK:

I'm sorry.

133 THE COURT:

1299.

134 MR. SHAPIRO:

99.

135 (Deft's 1299 for id = photograph)
136 MR. SCHECK:

Do you see a--do you agree and would you rely upon the statements at page 89 in formulating your opinions about this case?

137 DR. GERDES:

Yes.

138 MR. CLARKE:

Excuse me, objection. Hearsay as phrased.

139 THE COURT:

Overruled. Not as phrased. What paragraph are you talking about?

140 MR. SCHECK:

It is the first sentence and the beginning of the second paragraph.

141 MR. SCHECK:

Dr. Gerdes, do you agree with the observation of the NRC there that--

142 MR. CLARKE:

Excuse me. Objection, hearsay.

143 THE COURT:

Overruled.

144 MR. SCHECK:

--"Laboratory errors happen even in the best laboratories and even when the analyst is certain that every precaution against error was taken."

145 DR. GERDES:

I agree with that.

146 MR. SCHECK:

Now, are you familiar--your Honor, this is a chart entitled 1196, Mr. Yamauchi's diagram of the blood found at Rockingham. Now, Dr. Gerdes--

147 THE COURT:

All right. Dr. Gerdes, just take a half a step back, please. Thank you.

148 (Witness complies.)
149 MR. SCHECK:

Dr. Gerdes, are you familiar with Mr. Yamauchi's testimony that after handling Mr. Simpson's reference tube, opening it up, that he--creating the fitzco card, that he moved to the analysis of the Rockingham blood?

150 DR. GERDES:

Yes.

151 MR. SCHECK:

Have you reviewed his notes as to the parts of the glove that he manipulated?

152 DR. GERDES:

Yes.

153 MR. SCHECK:

And you are familiar with his testimony as to the initialing that he did in the wrist area of the glove?

154 DR. GERDES:

Yes.

155 MR. SCHECK:

The sample, the cutting, the pheno testing and the spot checks control that he did on the inside palmar surface and the back side of the glove?

156 DR. GERDES:

Yes.

157 (Brief pause.)
158 MR. SCHECK:

Your Honor, this is Prosecution's 272-A entitled "Rockingham glove results," a series of pictures.

159 MR. SCHECK:

Dr. Gerdes, are you familiar with the results obtained by the Department of Justice using the D1S80 PCR system obtaining results consistent with Mr. Simpson's 24, 25 genotype to a section near the wrist area entitled here G10, a section in the area depicted here as G11--G11 and a section indicated on the inside surface near the notch, G13?

160 DR. GERDES:

Yes.

161 MR. SCHECK:

All right. Given the manipulations that Mr. Yamauchi performed on the glove as depicted in his notes and the DNA test results from the amounts of DNA in that D1S80 system, in your opinion could they be the result of sample handling error?

162 MR. CLARKE:

Objection, calls for speculation.

163 THE COURT:

Sustained.

164 MR. SCHECK:

All right. Is it consistent with this DNA result that given the amounts of DNA in the D1S80 system that cross-contamination could have occurred in the areas marked G10, G11 and G13?

165 MR. CLARKE:

Same objection.

166 THE COURT:

Sustained.

167 MR. SCHECK:

Is it a good laboratory practice to have proceeded from handling the reference sample under the circumstances described by Mr. Yamauchi and turn to manipulation of the wrist area of the glove in the fashion that he described?

168 MR. CLARKE:

Objection, asked and answered.

169 THE COURT:

Overruled.

170 DR. GERDES:

No. It represents unacceptable risk of cross-contamination.

171 (Brief pause.)
172 MR. SCHECK:

Incidentally, are the amounts for G10, G11 and G13 on the D1S80 system, the amounts of DNA found in those areas, are those amounts consistent with cross-contamination from small amounts of blood?

173 MR. CLARKE:

Objection, no foundation, also calls for speculation.

174 THE COURT:

Sustained.

175 MR. SCHECK:

Are the amounts of DNA on the D1S80 results there within the nanogram range between two, three, nanogram range as reflected on the DOJ typing results?

176 MR. CLARKE:

Same objection, same grounds.

177 THE COURT:

Overruled.

178 DR. GERDES:

The total amount of DNA there is--I don't remember exactly the amount, but the point is that is a mixture, and in a mixture you can't really tell what proportion of the mixture is truly from one contributor or another, although the D1S80 typing result consistent with Mr. Simpson appears to be a minor contributor and that is consistent with the possibility of cross-contamination.

179 MR. SCHECK:

Now, could we have 1159-C.

180 (Brief pause.)
181 THE COURT:

I think I'm going to order that Mr. Harris not leave the courtroom while we are in session, and Mr. Cochran, it is so ordered.

182 MR. COCHRAN:

I think he was getting some charts, your Honor, I believe.

183 (Brief pause.)
184 THE COURT:

That is an order, Mr. Harris.

185 MR. SCHECK:

Is it a good laboratory practice to handle in the same period in the same location samples that have high DNA content and low DNA content?

186 MR. CLARKE:

Objection, asked and answered.

187 THE COURT:

Sustained I think we have visited that topic now for the third time.

188 MR. SCHECK:

All right. Well, let's move to the next one.

Temperature

tense

Key Quotes (5)

Dr. John Gerdes
The rules are that you never handle a reference sample at the same time as any evidence.
Establishes the standard forensic protocol that Gerdes argues LAPD violated, underpinning the entire contamination defense.
Dr. John Gerdes
That is not an acceptable practice in any forensic laboratory.
Direct condemnation of Yamauchi's June 14th sample handling — the defense's core attack on the DNA evidence chain.
Dr. John Gerdes
It is a vacutainer. That means it is under vacuum. It is sort of like opening a coffee can, you can hear it and there is an aerosol that is created.
Explains mechanistically how opening Simpson's reference tube could have dispersed blood DNA onto nearby evidence items.
Dr. John Gerdes
The D1S80 typing result consistent with Mr. Simpson appears to be a minor contributor and that is consistent with the possibility of cross-contamination.
Directly ties the Rockingham glove DNA results to the contamination theory — Simpson's DNA pattern appears as a minor contributor, consistent with trace contamination rather than primary deposition.
Lance A. Ito
And the nodding of the jurors indicate that they recollect that from this trial, too, and they recollect it from a month ago.
Rare judicial color commentary — signals jurors are engaged and tracking the contamination argument across weeks of testimony.

Evidence (8)

Defense 1299
Page 89 of the NRC report, stating 'Laboratory errors happen even in the best laboratories and even when the analyst is certain that every precaution against error was taken.'
Marked for identification; Gerdes confirmed he agrees with and relies on it
People's 272-A
Rockingham glove results — series of pictures showing DOJ DNA typing results for sections G10, G11, G13
Discussed; used to argue D1S80 results consistent with Simpson as minor contributor consistent with cross-contamination
1196
Mr. Yamauchi's diagram of blood found at Rockingham
Displayed in court during testimony
1185 (serology item description notes)
Yamauchi's notes for June 14th and 15th documenting his sample handling sequence
Referenced to establish timeline of reference sample + evidence sample processing
1159-C
Chart (not further described before session ended)
Called for but not yet displayed before transcript ends
Informal
Yamauchi's reference tube (vacutainer) of OJ Simpson's blood — spilled through chem wipe onto glove
Discussed; formed basis of aerosol/spillage contamination argument
+ 2 more

Notable Exchanges (3)

Barry ScheckDr. John GerdesGeorge Clarke
Scheck attempted to walk Gerdes through a hypothetical — Yamauchi writing with a pen contaminated by spilled blood and carrying it down the bench — but Clarke's speculation objection was sustained and the answer stricken.
strategic/frustrated
Lance A. ItoBarry Scheck
After Scheck asked the same contamination-risk question for the third time, Ito sustained Clarke's objection and pointedly noted 'I think we have visited that topic now for the third time,' cutting off that line.
judicial impatience
Lance A. ItoJohnnie Cochran
Ito ordered a Mr. Harris not to leave the courtroom while in session and repeated the order directly. Cochran explained Harris was retrieving charts.
procedural/firm

Light Moments (1)

Lance A. Ito / Barry Scheck
Ito observed jurors nodding at Gerdes's re-explanation of high-vs-low concentration contamination risk, quipping they remember it 'from a month ago' — Scheck deadpanned 'Well, it was a month ago.'

Credibility Attacks (2)

⚔ Gary Yamauchi (LAPD criminalist)
Prior testimony used to establish protocol violation
Scheck systematically walked Gerdes through Yamauchi's own testimony and notes to establish that his June 14th sample handling — opening Simpson's reference tube (which aerosolized and spilled), then processing the Rockingham glove and Bundy swatches in the same 9:00–11:20 AM session — violated universal forensic protocols against simultaneous reference/evidence handling.
⚔ LAPD DNA laboratory
Comparison to industry standards and NRC report
Gerdes testified that LAPD's practice of concurrent reference/evidence handling was 'not acceptable in any forensic laboratory,' contrasting it with Cellmark's practice of strict temporal separation. The NRC report citation further anchored the critique in published scientific authority.

Witness Demeanor

(Witness complies.) — stepped back from diagram at Ito's request
(Brief pause.) — multiple brief pauses during exhibit handling and transitions

Objections

24 objections (11 sustained, 8 overruled)
Proceeding 7145 • 188 utterances • Defense witness
Criminal Trial
Department 103
⚖️ Start
📂 AUG 2, 1995 📄 Direct examination of Dr. John
AUG 2, 1995 KRT DvH TD